The Urolift System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance

Applied Health Economics and Health Policy

Volumn 14, Issue 5, 2016, Pages 515-526

  Ray, Alistair ^a   Morgan, Helen ^a   Wilkes, Antony ^b   Carter, Kimberley ^c   Carolan Rees, Grace ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

^c NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL OUTCOME; COST EFFECTIVENESS ANALYSIS; ECONOMIC MODEL; ENUCLEATION; ERECTILE DYSFUNCTION; HEALTH CARE COST; HOLMIUM LASER; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MALE; MEDICAL SOCIETY; MINIMALLY INVASIVE PROCEDURE; NON INVASIVE SURGICAL DEVICE; PRACTICE GUIDELINE; PROSTATE HYPERTROPHY; PROSTATE LOBE; PROSTATE SURGERY; PROSTATIC URETHRAL LIFT; RETROGRADE EJACULATION; REVIEW; SEXUAL FUNCTION; SYSTEMATIC REVIEW (TOPIC); TRANSURETHRAL RESECTION; COMPLICATION; LOWER URINARY TRACT SYMPTOMS; PROSTHESES AND ORTHOSES; TREATMENT OUTCOME; URETHRA;

HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; PROSTATIC HYPERPLASIA; PROSTHESES AND IMPLANTS; TREATMENT OUTCOME; URETHRA;

EID: 84987870696     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-015-0218-x     Document Type: Review

References (37)

1. National Institute for Health and Care Excellence. Medical Technologies Evaluation Programme: Methods Guide. http://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-medical-technologies/Medical-technologies-evaluation-programme-methods-guide.pdf. Accessed 7 Apr 2015.
2. Campbell B, Campbell M. NICE medical technologies guidance: a novel and rigorous methodology to address a new health technology assessment challenge. Appl Health Econ Health Policy. 2012;10(5):295–7. Accessed 7 Apr 2015.
3. National Institute for Health and Care Excellence. Lower urinary tract symptoms. The management of lower urinary tract symptoms in men. Clinical guideline 97. http://www.nice.org.uk/guidance/cg97/resources/guidance-lower-urinary-tract-symptoms-pdf. NICE 2010; Accessed 7 April 2015.
4. National Institute for Health and Care Excellence. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. NICE 2014. http://www.nice.org.uk/guidance/ipg475. Accessed 7 Apr 2015.
5. National Institute for Health and Care Excellence. MTG217 The TURis system for transurethral resection of the prostate. https://www.nice.org.uk/guidance/mtg23. Accessed 15 March 2015.
6. National Institute for Health and Care Excellence. IPG17 Holmium laser prostatectomy. NICE 2003. https://www.nice.org.uk/guidance/ipg17. Accessed 7 Apr 2015.
7. National Institute for Health and Care Excellence. The UroLift system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (Scope). NICE 2014. https://www.nice.org.uk/guidance/gid-mt241/documents/the-urolift-system-for-the-treatment-of-lower-urinary-tract-symptoms-secondary-to-benign-prostatic-hyperplasia-final-scope2. Accessed 7 Apr 2015.
8. Perera M, Roberts RJ, Doi SAR, Bolton DM. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol. 2014. doi:10.1016/j.eururo.2014.10.031.
9. Delongchamps NB, Conquy S, Defontaines J, Zerbib M, Peyromaure M. [Intra-prostatic UroLift implants for benign prostatic hyperplasia: preliminary results of the four first cases performed in France]. [French]. Progres en Urologie 2012;22(10):590–597.
10. Abad PG, del Peso AC, Ojas BS, Arjona MF. UroLift (R), a new minimally invasive treatment for patients with low urinary tract symptoms secondary to BPH. Preliminary Results. Archivos Espanoles de Urologia. 2013;66(6):584–91.
11. Chin PT, Bolton DM, Jack G, Rashid P, Thavaseelan J, Yu RJ, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2012;79(1):5–11.
12. Woo HH, Bolton DM, Laborde E, Jack G, Chin PT, Rashid P, et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9(2):568–75.
13. Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013;190(6):2161–7.
14. Roehrborn CG, Gange S, Shore N, Giddens J, Bolton DM, Cowan BE, et al. Durability of the prostatic urethral lift: 2-year results of the LIFT study. Urol Pract. 2015;2:1–7.
15. McVary KT, Gange SN, Shore ND, Bolton DM, Cowan BE, Brown BT, et al. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med. 2014;11(1):279–87.
16. Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE, et al. Multicentre prospective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int. 2014;113(4):615–22.
17. Li S, Zeng XT, Ruan XL, Weng H, Liu TZ, Wang X, et al. Holmium laser enucleation versus transurethral resection in patients with benign prostatic hyperplasia: an updated systematic review with meta-analysis and trial sequential analysis. PLoS One. 2014;9(7):e101615.
18. Centre for Reviews and Dissemination and University of York. PROSPERO—International prospective register of systematic reviews. http://www.crd.york.ac.uk/prospero/.
19. Ahyai SA, Lehrich K, Kuntz RM. Holmium laser enucleation versus transurethral resection of prostate: 3-year follow-up results of a randomised clinical trial. Eur Urol. 2007;52:1456–63.
20. Kuntz RM, Ahyai SA, Lehrich K, Fayad A. Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients. J Urol. 2004;172:1012–6.
21. Eltabey MA, Sherif H, Hussein AA. Holmium laser enucleation versus transurethral resection of the prostate. Can J Urol. 2010;17:5447–52.
22. Gilling PJ, Mackey M, Cresswell M, Kennett K, Kabalin JN, Fraundorfer MR. Holmium laserversus transurethral resection of the prostate: a randomized prospective trial with 1-yearfollow-up. J Urol. 1999;162(5):1640–4.
23. Gupta N, Sivaramakrishna, Kumar R, Dogra PN, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40g. BJU Int. 2006;7:85–89.
24. Mavudura RM, Mandal AK, Singh SK, Acharya N, Agarwal M, Garg S, et al. Comparison of HoLEP and TURP in terms of efficacy in the early postoperative period and perioperative morbidity. Urol Int. 2009;82:130–5.
25. Montorsi F, Naspro R, Solania A, Suardi N, Briganti A, Zanoni M, et al. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol. 2004;172:1926–9.
26. Sun N, Fu Y, Tian T, Gao J, Wang Y, Wang S, et al. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a randomized clinical trial. Int Urol Nephrol. 2014;46(7):1277–82.
27. Tan A, Gilling PJ, Kennett K, Frampton C, Westenberg A, Fraundorfer MR. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol. 2003;170:1270–4.
28. Barry MJ, Williford WO, Machi M, Jones KM, Walker-Corkery E, Lepor H. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is perceptible to patients? J Urol. 1995;154:1770–4.
29. Bachmann A, Tubaro A, Barber N, d’Ancona F, Muir G, Witzsch U, et al. A European Multicenter Randomized Noninferiority Trial Comparing 180 WGreenLight XPS Laser Vaporization and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 12-Month Results of the GOLIATH Study. J Urol. 2015;193(2):570–8.
30. Gilling PJ, Aho TF, Frampton C, King CJ, Fraundorfer MR. Holmium laser enucleation of the prostate: results at 6 years. Eur Urol. 2008;53:744–9.
31. Lourenco T, Armstrong N, N'Dow J, Nabi G, Deverill M, Pickard R, Vale L, MacLennan G, Fraser C, McClinton S, Wong S, Coutts A, Mowatt G, Grant A. Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technol Assess. 2008;12(35):169–515.
32. Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfus Med. 2003;13(4):205–18.
33. NHS Blood and Transplant. NHS Blood and Transplant Price List 2015–16. http://hospital.blood.co.uk/media/27457/price_list_2015-16.pdf. Accessed 26 Jan 2015.
34. Information Services Devision Scotland. ISD Scotland RX040X specialty costs and activity (inpatients in all specialties (exc long stay), by board). http://www.isdscotland.org/Health-Topics/Finance/Publications/2012-11-27/Costs_R040X_2012.xls. Accessed 26 Jan 2015.
35. National Health Service Reference Costs. NHS Reference Costs 2012–2013. https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013. Accessed 26 Jan 2015.
36. Roehrborn C, Gange S, Shore N, Giddens J, Bolton D, Cowan BE, et al. Three year durability of the prostatic urethral lift for BPH: results of a prospective, Multi-center, Randomized Study. J Urol. 2015;193(4 (Supplement)):e92.
37. Sonsken J, Barber N, Speakman M, Berges R, Wetterauer U, Greene D, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 Study. Eur Urol. 2015;68(4):643–652.